Search - tctmd.com

Displaying 781 - 800 of 1435

Sort: Relevancy | Date

For ‘Torrential’ Tricuspid Regurgitation, Two New Transcatheter Devices Safe, Effective in Early Results

News Conference News TCT 2017

For ‘Torrential’ Tricuspid Regurgitation, Two New Transcatheter Devices Safe, Effective in Early Results

Yael L. Maxwell

November 02, 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

News Conference News TCT 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

November 01, 2017

Debate: With Improved Technology and Optimal Technique ABSORB Will Become a Widely Used Device

Presentation TCT 2017

Debate: With Improved Technology and Optimal Technique ABSORB Will Become a Widely Used Device

Presenter: Stephen G. Ellis, Takeshi Kimura, Hiram G. Bezerra

October 31, 2017

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

Presentation TCT 2017

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

Presenter: Azeem Latib, Gregg W. Stone

October 31, 2017

REVASCTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

News Conference News TCT 2017

REVASC: CTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

October 31, 2017

Long-term Absorb BVS Data Continue to Disappoint

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

News Daily News

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Michael O'Riordan

October 11, 2017

Asymptomatic Carotid Artery Stenosis: When to Screen and When to Intervene

News Daily News

Asymptomatic Carotid Artery Stenosis: When to Screen and When to Intervene

October 05, 2017

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

News Conference News PCR London Valves 2017

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

September 27, 2017

Rivaroxaban, Warfarin Provide Similar Results Early After Mild Strokes Related to A-fib

News Daily News

Rivaroxaban, Warfarin Provide Similar Results Early After Mild Strokes Related to A-fib

September 14, 2017

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Industry News

Protembis announces successful first-in-human use of its ProtEmbo® Cerebral Protection System in European trial

September 05, 2017

Less Is More? Health Benefits of Fruits, Vegetables, and Legumes Seen at Lower Intake Levels

News Conference News ESC 2017

Less Is More? Health Benefits of Fruits, Vegetables, and Legumes Seen at Lower Intake Levels

Michael O'Riordan

August 29, 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

News Conference News ESC 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

August 27, 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.